Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials (Q34579246)

3 August 2017

1 reference

title

Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials (English)

1 reference

3 August 2017

1 reference

M B Atkins

1

1 reference

3 August 2017

J Dutcher

2

1 reference

3 August 2017

G Weiss

3

1 reference

3 August 2017

K Margolin

4

1 reference

3 August 2017

J Clark

5

1 reference

3 August 2017

J Sosman

6

1 reference

3 August 2017

T Logan

7

1 reference

3 August 2017

F Aronson

8

1 reference

3 August 2017

J Mier

9

1 reference

3 August 2017

Cytokine Working Group

10

1 reference

3 August 2017

publication date

1 January 2001

1 reference

3 August 2017

1 reference

3 August 2017

volume

18

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

197-207

1 reference

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

3 August 2017

cites work

1 reference

12 December 2020

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

1 reference

12 December 2020

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

12 December 2020

Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

1 reference

12 December 2020

Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

1 reference

12 December 2020

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

12 December 2020

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie

1 reference

12 December 2020

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

1 reference

12 December 2020

Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma

1 reference

12 December 2020

A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.

1 reference

12 December 2020

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

12 December 2020

In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells

1 reference

12 December 2020

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen

1 reference

12 December 2020

Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer

1 reference

12 December 2020

Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.

1 reference

12 December 2020

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

12 December 2020

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administrat

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects

1 reference

12 December 2020

Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro

1 reference

12 December 2020

Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses

1 reference

12 December 2020

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

1 reference

12 December 2020

Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.

1 reference

12 December 2020

Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study

1 reference

12 December 2020

Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells

1 reference

12 December 2020

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma

1 reference

12 December 2020

An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer

1 reference

12 December 2020

In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors

1 reference

12 December 2020

Identifiers

DOI

10.1385/MO:18:3:197

1 reference

Dimensions Publication ID

3 August 2017

1022686885

0 references

1 reference